Microsoft, weight loss drug sales, and GSK profits surge

January 31, 2024

In today's episode, Ian King speaks with Dan Ives - managing director of the brokerage and advisory firm Wedbush Securities - to discuss Microsoft's revenues and AI.

Ian Johnston, global pharmaceutical correspondent at the Financial Times, discusses sales of popular weight loss drug 'Wegvoy', made by Novo Nordisk - as they say their sales almost quadrupled last year.

And, Ian discusses GSK's operating profit of £8.8bn for 2023 with strong selling medicines including its HIV and shingles medication.

Rate this item

(0 votes)

« Mayors hold 'constructive' HS2 talks with transport secretary Fed takes step towards first US rate cut but signals extended caution »